Contineum Therapeutics Shares Surge on Positive Bristol Myers Squibb Trial Results

Key Facts

1Contineum Therapeutics shares surged following Bristol Myers Squibb's announcement that its Phase 3 trial for Admilparant met its primary endpoint.

Contineum Therapeutics shares surged following Bristol Myers Squibb's announcement that its Phase 3 trial for Admilparant met its primary endpoint. Investing.com reported that the successful clinical results served as a major catalyst for the company's valuation.

CTNM closed at $13.38 on October 9, 2026, prior to the news of the trial success. The achievement of Phase 3 milestones is considered a significant development in the biotech sector, highlighting the shared interests between Contineum Therapeutics and Bristol Myers Squibb in the drug's development.